Skip to main content
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Toggle navigation
Login
Search
Home
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Track
Home
Browse by Track
Browse by Track
Type here to filter the list
Basic Science
(2)
5: SETD2 loss in kidney cancer - Setting the stage for synthetic lethality
Favorite
7: New Evidence of Preventing Kidney Tumor Progression in Pre-clinical Mouse Model
Favorite
Case Report
(1)
27: Renal cell carcinoma in a patient with Situs Inversus Totalis – Laparoscopic radical nephrectomy is a safe and feasible option: A case report
Favorite
Imaging
(1)
8: PSMA-expression in renal cell carcinoma as basis for theranostic approaches – an immunohistochemical nephrectomy study
Favorite
Impact of COVID-19
(1)
9: Perceptions of COVID-19 vaccination in patients with renal cell carcinoma (RCC)
Favorite
Other
(1)
27: Renal cell carcinoma in a patient with Situs Inversus Totalis – Laparoscopic radical nephrectomy is a safe and feasible option: A case report
Favorite
Patient-Reported Outcomes
(3)
2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey
Favorite
10: Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)
Favorite
28: A Three-Arm Randomized Multicenter Phase II Trial Comparing Patient-Reported Outcome (PRO) Monitoring in Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma: ePRO vs paper-PRO, or usual care (Trial in Progress)
Favorite
Quality of Care and Quality Improvement
(2)
3: A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer
Favorite
11: Retention in clinical trials: the kidney cancer patient perspective
Favorite
Real-world Evidence
(7)
4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
Favorite
12: Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)
Favorite
13: Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study
Favorite
14: Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany
Favorite
15: Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.
Favorite
16: Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT
Favorite
17: Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany
Favorite
Regular Abstract
(25)
1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER
Favorite
2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey
Favorite
3: A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer
Favorite
4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
Favorite
5: SETD2 loss in kidney cancer - Setting the stage for synthetic lethality
Favorite
7: New Evidence of Preventing Kidney Tumor Progression in Pre-clinical Mouse Model
Favorite
8: PSMA-expression in renal cell carcinoma as basis for theranostic approaches – an immunohistochemical nephrectomy study
Favorite
9: Perceptions of COVID-19 vaccination in patients with renal cell carcinoma (RCC)
Favorite
10: Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)
Favorite
11: Retention in clinical trials: the kidney cancer patient perspective
Favorite
12: Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)
Favorite
13: Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study
Favorite
14: Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany
Favorite
15: Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.
Favorite
16: Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT
Favorite
17: Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany
Favorite
18: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)
Favorite
19: From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up
Favorite
20: Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy
Favorite
21: AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma
Favorite
22: Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
Favorite
23: Relationship between circulating immune markers and tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab within the NIVOREN study.
Favorite
24: Circulating microRNAs and treatment response to cabozantinib in metastatic clear cell renal cell carcinoma (mRCC) patients treated in the phase II CABOPRE trial.
Favorite
25: Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Favorite
26: Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature
Favorite
Therapeutics
(7)
1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER
Favorite
18: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)
Favorite
19: From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up
Favorite
20: Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy
Favorite
21: AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma
Favorite
29: LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Favorite
30: Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study
Favorite
Treatment Toxicities and Symptom Management
(1)
22: Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
Favorite
Trial-in-progress Abstract
(4)
28: A Three-Arm Randomized Multicenter Phase II Trial Comparing Patient-Reported Outcome (PRO) Monitoring in Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma: ePRO vs paper-PRO, or usual care (Trial in Progress)
Favorite
29: LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Favorite
30: Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study
Favorite
31: AURORAX-0087A: Glycosaminoglycan (GAG) scores for recurrence detection in Leibovich Points ≥5 clear cell renal cell carcinoma - Trial In Progress
Favorite
Tumor Biology, Biomarkers, and Pathology
(5)
23: Relationship between circulating immune markers and tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab within the NIVOREN study.
Favorite
24: Circulating microRNAs and treatment response to cabozantinib in metastatic clear cell renal cell carcinoma (mRCC) patients treated in the phase II CABOPRE trial.
Favorite
25: Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Favorite
26: Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature
Favorite
31: AURORAX-0087A: Glycosaminoglycan (GAG) scores for recurrence detection in Leibovich Points ≥5 clear cell renal cell carcinoma - Trial In Progress
Favorite
Back to Top
